| Date | Title | Description | |
|---|---|---|---|
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 03 Nov 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 27 October and 2 November 2023 | Download |
| 27 Oct 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 20 October and 26 October 2023 | Download |
| 20 Oct 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 13 October and 19 October 2023 | Download |
| 13 Oct 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 6 October and 12 October 2023 | Download |
| 06 Oct 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 29 September and 5 October 2023 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |